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Introduction
Pancreatic carcinoma is the fourth leading cause of 
cancer related death in the Western world and the third 
most common malignancy of the gastrointestinal tract 
(Siegel, Naishadham and Jemal, 2013). The aggressive 
nature of the disease coupled with advanced stage at 
diagnosis in most cases, results in 5 year survival rate 
of less than 5% (Jemal et al., 2005). Surgical resection 
offers the only chance of cure but less than 15 to 20% 
are resectable at initial diagnosis (Parvez and Dawood, 
2003). Median survival ranges from 8 to 12 months for 
locally advanced unresectable disease and 3 to 6 months 
for patients presenting with metastasis (Siegel et al., 2013). 
Chemotherapy has traditionally been the backbone 
of treatment for advanced pancreatic carcinoma and has 
evolved over time with gemcitabine based treatment 
occupying the niche of “standard of care” until recently 
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Abstract
 Background: Pancreatic cancer is the fourth leading cause of cancer related death with median survival 
ranging from 3 to 6 months for metastatic disease. Palliative chemotherapy has been the backbone of treatment 
in advanced stage and has evolved over time. Data pertaining to the disease are scarce from our part of the world 
where treatment poses a significant challenge due to lack of resources. Materials and Methods: A retrospective 
chart review was performed for all patients presenting with stage IV pancreatic carcinoma at a tertiary care 
hospital in Karachi, Pakistan between January 2008 and December 2012. Data were collected using a pre-designed, 
coded questionnaire looking at patient characteristics, treatment given and outcome. Results: 101 patients were 
found to be eligible. Mean age was 56.7 ± 12.8 years, the male to female ratio was 2:1 and most patients had a 
good performance status. More than half of the tumors were located in the head (57%, n=58) and almost all 
were adenocarcinomas (95%, n=96). Some 58% (n=59) received first line chemotherapy of which 49% (n=29) 
received gemcitabine-based regimens and 39% (n=23) received FOLFIRINOX. The median progression free 
survival for gemcitabine based treatment was 2.9 months (IQR=1.6-5.6) as opposed to 7.3 months (IQR=4.5-9.2) 
for FOLFIRINOX (P=0.02). Median overall survival was 4.9 months (IQR=2.3-9.5) for first line gemcitabine 
based treatment and 10.5 months (IQR=7.0-13.2) for first line FOLFIRINOX therapy (P=0.002). Patients on 
FOLFIRINOX had better survival across all subgroups. Inpatient admissions and dose reductions were more 
frequent with FOLFIRINOX but the difference between the two regimens was not statistically significant. 
FOLFIRINOX could be successfully administered as outpatient therapy to a number of patients. Conclusions: 
FOLFIRINOX remains a suitable first line option in patients with metastatic pancreatic cancer with good 
performance status even in a resource-poor country where diagnostic and supportive care facilities may be less 
than optimal and cost is a limitation. 
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(Di Marco et al., 2010). Gemcitabine therapy was 
established as standard of care in advanced pancreatic 
carcinoma back in 1997 (Burris et al., 1997) and since 
then numerous studies have validated a median overall 
survival of 6 months in advanced disease when the drug 
has been used as a single agent (Conroy and Mitry, 2011). 
Doublet chemotherapy has some benefit in response rate 
(RR) and progression free survival (PFS) without any clear 
difference in overall survival (OS) (Cunningham et al., 
2009). One promising emerging chemotherapeutic option 
is the nab-Paclitaxel plus Gemcitabine combination which 
has been shown to be effective (Von Hoff et al., 2013).
Improvement in the understanding of the molecular 
biology of pancreatic cancer has led to an increased 
effort to develop new management strategies. It is hoped 
that these modalities will help improve the outcome of 
advanced pancreatic carcinoma in the future (Valsecchi 
et al., 2014).
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In May 2011, Conroy et al. published their experience 
with FOLFIRINOX (combination chemotherapy 
comprising oxaliplatin, irinotecan, folinic acid and 
5-fluorouracil) where they reported a significant survival 
benefit in comparison to Gemcitabine based chemotherapy 
(Conroy et al., 2011). Although it has now been established 
in the West as the preferred regimen for patients with 
metastatic pancreatic cancer with good performance status 
and a normal serum bilirubin level (Conroy et al., 2011), 
no report from Asian trials or documented anecdotal 
experience of its use from South Asia is available (Conroy 
et al., 2013). A recently reported study has evaluated 
XELOX as 2nd line therapy in an Asian population with 
encouraging anti-tumor activity and manageable toxicity, 
laying the foundation for further research exploring 
FOLFIRINOX as a potential first line regimen in this 
population (Bayoglui et al., 2014).
Pakistan with the sixth highest world population 
and increasing burden of cancer including pancreatic 
carcinoma has a similar trend, with most patients 
presenting at an advanced stage. There is a paradigm 
shift towards FOLFIRINOX as the preferred treatment 
regimen in appropriately selected patients but no report 
of the outcome, adverse events and challenges with the 
treatment are available. Maintaining intravenous lines 
for 5-FU infusion pump with high incidence of infection 
due to poor hygiene, increased cost of FOLFIRINOX 
over gemcitabine and poor educational background were 
reasons for reservation of this regimen in our population. 
Generally, there is dearth of data regarding experience with 
FOLFIRINOX from South Asia where the documentation 
of this experience is also of paramount importance because 
of the genetic and cultural variability of the region from 
the West. 
This study was undertaken to estimate the burden of 
stage IV pancreatic carcinoma at a major tertiary care 
center in Karachi, Pakistan. We aimed to reflect upon the 
management options used for metastatic disease at our 
center, specifically highlighting differences in responses 
between major treatment groups and the survival patterns 
of these patients despite the local challenges.
Materials and Methods
Patients
Retrospective data was collected for adult patients 
(≥16 years) with recently diagnosed (histopathologically 
or cytologically confirmed) primary metastatic pancreatic 
carcinoma presenting to the Aga Khan University Hospital 
(AKUH), Karachi between January 1, 2007 and December 
31, 2012. Patients were identified using the International 
Classification of Diseases (ICD) coding system and the 
cancer registry at AKUH. Patients had to be treatment 
naive with no prior history of malignancy to be included 
in the study.
Data was collected using a pre-designed and coded 
questionnaire approved by the institutional Ethical Review 
Committee. Details of demographics, symptomatology, 
risk factors, diagnostic modalities used, histopathological 
features, and outcome were collected for all patients. 
Follow up records, data pertaining to therapies and 
dates of last contact were also recorded. 
Statistical analysis
Statistical Package for Social Sciences (SPSS) version 
19 was used to perform data analysis on 101 eligible 
patients. Data was reported as mean ± standard deviation 
for continuous variables and proportions and percentages 
for categorical data. Continuous variables not following 
the normal distribution were reported as medians along 
with inter-quartile ranges. 
Analysis was performed on the entire cohort 
followed by a subgroup analysis according to the 2 major 
chemotherapy regimens employed (Gemcitabine based 
regimens vs. FOLFIRINOX). Categorical variables in the 
subgroups were compared using the Pearson Chi Square 
test or Fischer’s test while the Student’s t-test was used 
to compare continuous data. Median PFS and median 
OS were calculated in the two groups and Kaplan Meier 
curves were generated. Median PFS in the two groups 
was compared using the log-rank test while median OS 
was compared using the Mann-Whitney test. P value less 
than 0.05 was considered significant.
Results 
Patients
101 eligible patients with metastatic pancreatic 
carcinoma presented to our institution between January 
1, 2007 and December 31, 2012 [Table 1]. The mean 
age of the study population was 56.7±12.8 years and the 
male to female ratio was 2:1. Most patients had a good 
performance status at diagnosis (84%, n=85). More than 
half of the tumors were located in the head of the pancreas 
(57%, n=58) and almost all were adenocarcinomas (95%, 
n=96). The most common clinical presentations included 
abdominal pain (95%, n=96), weight loss (88%, n=89), 
icterus (55%, n=55) and worsening of established type 
2 Diabetes (40%, n=40). Deep venous thrombosis was a 
presenting feature in 23% of patients (n=23). 
On subgroup analysis, the baseline characteristics, 
clinical presentations and laboratory parameters were 
similar between the two groups divided according to the 
two major chemotherapy regimens employed (Table 1). 
The only notable difference was the presence of a larger 
number of patients with an abnormal serum level of 
CA-19-9 in the Gemcitabine group as compared to the 
FOLFIRINOX group (72% vs. 48%). The relative absence 
of patients with jaundice in the FOLFIRINOX group can 
be attributed to the pharmacological limitation of using 
hepatotoxic agents in patients with grossly abnormal 
bilirubin levels (11).
Treatment
Almost half of the study population (42%, n=42) 
presented at a stage where chemotherapeutic intervention 
was not possible and received palliative surgical 
intervention (n=10) or comfort care (n=32) . Of the 
remaining 59 patients who were clinically suitable to 
receive first line chemotherapy, 49% (n=29) received 
Gemcitabine based regimens, 39% (n=23) received 
FOLFIRINOX whereas 12% (n=7) were treated with other 
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chemotherapeutic regimens.
The median number of cycles received by patients in 
the Gemcitabine group were 4 (IQR=3-7.5) as opposed 
to 16 (IQR=9-19) in the FOLFIRINOX group (p<0.001). 
This corresponded to a median duration of 12.8 weeks 
(IQR=7.4-25.1) for patients on Gemcitabine versus 35.8 
weeks (IQR=21.6-41.6) for patients in the FOLFIRINOX 
group (p<0.001).
The most common grade 3 and 4 side effects with first 
line Gemcitabine were elevated Alanine transaminase 
(ALT) 14% (n=4), febrile neutropenia 10% (n=3) and 
thrombocytopenia 7% (n=2) whereas for first line 
FOLFIRINOX, these were febrile neutropenia (22%, n=5), 
thrombocytopenia (22%, n=5), peripheral neuropathy 
(9%, n=2) and diarrhea (9%, n=2) [Table 2]. 
Although the frequency of side effects, dose reductions 
and patients requiring inpatient admissions were more 
common in the group receiving FOLFIRINOX, the 
difference between the 2 groups was not found to be 
statistically significant [Table 2].
Only 18 patients (18%) received any second-line 
chemotherapy out of which 7 (39%) received Gemcitabine 
based therapy, 5 (28%) received Capecitabine based 
treatment and 4 (22%) were given FOLFIRINOX. The 
number of patients receiving second line chemotherapy 
was too small for meaningful analysis.
Outcome
At 6 months followup, only 24% of patients (n=24) 
from the entire cohort were alive. All 42 patients who had 
not received any chemotherapy had died. At the one year 
interval the percentage of surviving patients had dropped 
to an even more dismal 13% (n=13). 
On subgroup analysis according to the two major 
chemotherapy groups, only 24% (n=7) patients in 
Gemcitabine group were alive as opposed to 61% (n=14) 
on FOLFIRINOX at the 6 month interval (p<0.001). 
This difference in overall survival remained statistically 
significant at 1 year followup as well (17% Gemcitabine 
vs. 26% FOLFIRINOX, p=0.008).
Table 1. Baseline Characteristics of the Study Population
Variables All metastatic 1st line Gemcitabine 1st line FOLFIRINOX
 pancreatic cancers n=101 based treatment n=29 n=23
Age, Mean (SD) 56.7 (12.8) 54.4 (12.4) 51.9 (10.5)
 ≤40 (%) 13 (12.9) 4 (13.8) 4 (17.4)
 >40 (%) 88 (87.1) 25 (86.2) 19 (82.6)
 Gender, Male (%) 69 (68.3) 19 (65.5) 14 (60.9)
ECOG Performance Status   
 0 to 2 85 (84.2) 28 (96.6) 23 (100)
 3 to 4 16 (15.8) 1 (3.4) -
Site of Tumor   
 Head (%) 58 (57.4) 14 (48.3) 13 (56.5)
 Body/tail (%) 43 (42.6) 15 (51.7) 7 (43.5)
Diagnosis   
 Adenocarcinoma (%) 96 (95) 29 (100) 22 (95.7)
 Other (%) 5 (5) - 1 (4.3)
Symptoms   
 Abdominal Pain (%) 96 (95) 27 (93.1) 22 (95.7)
 Weight Loss (%) 89 (88.1) 26 (89.7) 17 (73.9)
 Jaundice (%) 55 (54.5) 14 (48.3) 10 (43.5)
 Worsening of Diabetes (%) 40 (39.6) 9 (31) 9 (39.1)
 DVT (%) 23 (22.8) 6 (20.7) 3 (13.0)
Laboratory Parameters   
 Total bilirubin > 2 (%) 48 (47.5) 12 (41.4) 4 (17.4)
 Normal CA-19-9  27 (26.7) 8 (27.6) 12 (52.2)
Table 2. Grade 3-4 Adverse Effects, Dose Reduction and In-Patient Admission Data
Variables All metastatic pancreatic 1st line Gemcitabine 1st line p value
 cancers receiving 1st line based treatment FOLFIRINOX 
 chemotherapy (n=52) (n=29) (n=23)
Major Side Effects of Chemotherapy 
 Thrombocytopenia (%) 7 (13.5) 2  (6.9) 5 (21.7) 
 Febrile Neutropenia (%) 8 (15.4) 3 (10.3) 6 (21.7) 
 Peripheral Neuropathy (%) 2  (3.8) 0  (0) 7 (21.7) 
 Diarrhea (%) 3  (5.8) 1  (3.4) 8 (21.7) 
 Mucositis (%) 1  (1.9) 0  (0) 9 (21.7) 
 AKI (%) 2  (3.8) 1  (3.4) 10 (21.7) 
 Elevated ALT (%) 5  (9.6) 4 (13.8) 11 (21.7) 
 Dose Reduction Needed (%) 7 (13.4) 2  (6.9) 5 (21.7) 0.12
 Admission Required (%) 15 (28.8) 8 (27.6) 7(30.4) 0.82
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The median PFS for patients on first line Gemcitabine 
based chemotherapy was 2.9 months (IQR=1.6-5.6) as 
opposed to 7.3 months (IQR=4.5-9.2) for patients on first 
line FOLFIRINOX (p=0.003) [Figure 1].
The median OS was 4.9 (IQR=2.3-9.5) months for 
the Gemcitabine and 10.5 (IQR=7.0-13.2) months for the 
FOLFIRINOX group (p=0.002) [Figure 2]. The median 
OS for the entire cohort was 4.7 months (IQR=2.1-8.6). 
Patients on FOLFIRINOX had better survival across 
all subgroups when compared with patients who had 
received Gemcitabine [Table 3].
Stratified subgroup analysis
A stratified subgroup analysis was carried out to look 
for the effect of age, gender, ECOG performance status, 
total bilirubin, CA 19-9 and site of tumor on outcome 
within each therapeutic sub-group. No statistically 
significant contribution of these variables was noted on 
outcome during analysis [Table 3]. It is possible that a 
difference may not have been elucidated due to the small 
number of patients in the sub-groups. 
Discussion
Although small, our study is the first describing 
experience with FOLFIRINOX in the South Asian 
population. The results from our study reiterate a significant 
survival benefit with FOLFIRINOX when compared to 
gemcitabine based treatment. The approximate doubling 
of both PFS (7.3 vs. 2.9 months) and OS (10.5 vs. 4.9 
months) with FOLFIRINOX vs. Gemcitabine based 
therapy mirrors the results of the pivotal paper by Conroy 
et al. (2011) and is similar to the OS reported in other 
Western studies (Peddi et al., 2012; Gunturu et al., 2013). 
The survival at one year in the FOLFIRINOX group in 
our study was lower than the one reported in Conroy’s 
study (48% vs. 26%) which may be secondary to the lower 
number of patients in our study. 
These results suggest that the therapeutic benefits 
of FOLFIRINOX over Gemcitabine hold true for the 
Asian population as well as in our clinical setting. This 
coupled with the observation that FOLFIRINOX confers 
approximately the same benefit across all patient sub-
groups further adds to the value of the regimen [Table 3]. 
The only subgroup of patients which showed an inferior 
survival amongst patients receiving FOLFIRINOX in our 
study was that of <40 year olds. However no definitive 
inference can be made due to the small number of patients 
in this subgroup. 
One may argue that a higher proportion of patients in 
the FOLFIRINOX group in our study had a normal CA 
19-9 at presentation and may have been responsible for 
the better prognosis seen with this chemotherapy regimen 
as it has been reported to be a predictor of better survival 
Figure 1. Kaplan-Meier Curve for Progression Free 
Survival (PFS)
Figure 2. Kaplan-Meier Curve for Overall Survival 
(OS)
Table 3. Subgroup and Stratified Subgroup Analysis
Variables Median survival Median Survival Median Survival 
 All cases (n=101) Gemcitabine (n=29) FOLFIRINOX (n=23)
 Months (IQR) Months (IQR) Months (IQR)
Age Entire cohort 4.7 (2.1-8.6) 4.9 (2.3-9.5) 10.5 (7.0-13.2)
 ≤40  6.9 (3.0-11.2) 7.9 (3.0-15.4) 7.1 (2.8-10.2)
 >40  4.6 (1.9-8.3) 4.9 (2.3-7.9) 10.8 (7.2-15.1)
Gender Male 4.1 (1.8-8.0) 5.1 (4.3-11.3) 10.6 (6.3-13.7)
 Female 4.1 (1.8-8.0) 2.2 (1.2-5.1) 10.6 (6.3-13.7)
ECOG  ECOG 0-2 5.3 (2.4-10.4) 4.9 (2.4-10.0) 10.5 (7.0-13.2)
 ECOG 3-4 1.8 (1.2-2.5) 2.3 (n=1) -
Total Bilirubin < 2 mg/dl 5.4 (2.2-10.1) 4.2 (2.2-5.0) 10.4 (7.0-11.9)
 ≥ 2mg/dl 3.2 (1.8-7.3) 9.0 (4.8-15.5) 13.0 (6.5-16.6)
CA-19-9 Normal 10.0 (2.5-15.3) 4.9 (2.3-7.9) 8.8 (6.2-11.1)
 Abnormal 3.8 (1.8-6.4) 4.7 (2.5-15.5) 13.0 (6.5-16.6)
Site of tumor Head 5.1 (2.3-10.1) 5.7 (4.7-11.9) 10.8 (6.2-15.2)
 Body/tail 3.2 (1.7-8.4) 2.5 (1.4-6.2) 10.3 (7.2-11.6)
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in chemo-naive patients (Berger et al., 2004; Waraya et 
al., 2009; Ballehaninna and Chamberlain, 2012). This 
hypothesis is however refuted by the fact that the survival 
benefit inferred by the normal serum CA 19-9 levels in 
chemo-naive metastatic pancreatic carcinoma patients, 
was lost when patients received any chemotherapy [Table 
3]. This is an interesting observation though and one which 
can be further explored. 
Another interesting observation in the group which 
received first line Gemcitabine was patients with a raised 
bilirubin level and those with tumors of the head of the 
pancreas fared better than those with normal bilirubin and 
tumors elsewhere in the pancreas. One may speculate that 
patients with tumors of the head of the pancreas would 
more likely present early secondary to extrinsic biliary 
obstruction and jaundice, resulting in better outcome, but 
in the end these were all stage IV patients. 
One of the major limitations of FOLFIRINOX has 
been the higher frequency of adverse effects observed 
with the regimen (Ko 2011). The skepticism associated 
with FOLFIRINOX use has somewhat been dispelled 
with the use of the regimen in several studies in the West 
which despite indicating a clearly significant increase 
in adverse events with its use, also prove that these are 
easily manageable with appropriate therapy (Conroy 
et al., 2011; Peddi et al., 2012; Gunturu et al., 2013). A 
similar trend was seen in our study where although the 
frequency of grade 3 and 4 side effects were higher in the 
FOLFIRINOX group, they were not significantly different 
from the Gemcitabine group and were manageable with 
adequate treatment when they did occur. Also patients 
received more weeks of treatment in FOLFININOX 
group compared to Gemcitabine based chemotherapy. 
This highlights the fact that the regimen is reasonably well 
tolerated in our population and in light of the statistically 
significant survival benefit conferred; the slightly 
unfavorable toxicity profile may well be acceptable to 
patients and clinicians worldwide. 
Experimentation with modifications to the 
FOLFIRINOX regimen have been carried out to reduce 
toxicity without compromising on the efficacy and a recent 
study by Mahaseth et al. which deleted 5-FU bolus from the 
regimen while employing routine use of GCSF, has shown 
to be better tolerated while achieving disease control in 
most patients (Mahaseth et al., 2013). Researchers 
elsewhere have employed reduced median relative doses 
of FOLFIRINOX but have managed to maintain efficacy 
(Gunturu et al., 2013). These modifications may eventually 
result in further improving the toxicity profile of the 
regimen making it more palatable.
An important factor dictating the acceptance of 
FOLFIRINOX in a resource poor country like Pakistan 
is the cost associated with its use. Although the regimen 
has been proclaimed as cost-effective (Mahaseth et 
al., 2013), the substantial out of pocket disbursement 
necessary in our country has the potential of limiting its 
use to the affluent only. An estimate of the difference in 
cost calculated at the end of six weeks of therapy between 
the two regimens indicates FOLFIRINOX to be twice as 
expensive as Gemcitabine based treatment ($1524 vs. 
$762). Until recently FOLFIRINOX was given solely 
as inpatient treatment, but with the recent availability 
of outpatient infusion pumps we have transitioned the 
regimen to an out-patient setting without a distinct increase 
in complication rates or side effects in an economically 
transitioning country with less than optimal hygienic 
conditions. This change has further reduced the cost of 
regimen and it is possible that modifications in the regimen 
itself (e.g. deletion of 5-FU bolus) may make it even more 
affordable in the near future.
Our study has certain limitations. One of the most 
imminent limitations is the retrospective nature of 
collection of data through hospital records. This has the 
potential for incomplete data collection due to missing 
information in the charts. In our defence, most of our 
variables are laboratory investigations, treatment related 
variables and survival data which are documented in 
detail at our institution and hence are less likely to create 
bias because of incomplete information. Secondly, this is 
a single center study and it can be argued that the results 
cannot be generalized to the local population at large. The 
fact that metastatic pancreatic carcinoma is a rare disease 
and Aga Khan University is the major tertiary care center 
catering to patients from all over the country, we can 
speculate to generalize the result as the numbers in each 
individual subgroup seems reasonable. Finally, an element 
of bias that could not be controlled was the difference in 
calendar time for receiving the two major chemotherapy 
regimens. Gemcitabine based chemotherapy was solely 
prescribed till 2 years ago when it was the standard of 
care whereas FOLFIRINOX became practice recently. 
This difference has the potential of skewing the survival 
results in favor of FOLFIRINOX as part of the survival 
benefit may be due to improved supportive care and other 
secular trends over time. 
In conclusion, our study attempts to fill the void of 
information currently present pertaining to pancreatic 
cancer in our country. It highlights the baseline 
characteristics and outcomes of patients presenting with 
metastatic disease to our institution. To the best of our 
knowledge this is the first study from South Asia narrating 
experience with FOLFIRINOX and hence it is also the 
first to compare the regimen with Gemcitabine based 
chemotherapy. 
We strongly believe that the results of this study 
should be able to instill enough confidence in physicians 
in the region to use the regimen as first line treatment 
in appropriately selected patients even in a resource 
challenged country such as ours.
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